Results 131 to 140 of about 1,555,632 (211)

Hope as a Therapeutic Imperative for Treatment Resistant Depression. [PDF]

Bipolar Disord
Ng QX.
europepmc   +1 more source

Comment on "Serum Amyloid β Oligomer May Predict Treatment Response in Middle-Aged and Late-Life Patients With Depression". [PDF]

Neuropsychopharmacol Rep
Škudar S.
europepmc   +1 more source

Supporting the Primary Outcomes of the Mirai Trial for the Adjunctive Digital Therapeutic Rejoyn (CT-152) in the Treatment of Major Depressive Disorder: Meaningful Change Analysis in the Montgomery-Åsberg Depression Rating Scale. [PDF]

JMIR Form Res
Hudgens S, Purnajo I, Floden L, Hwang S, Ash J, Rothman B, Speier A, Forbes A.   +7 more
europepmc   +1 more source

[Antidepressive agents].

Wiadomosci lekarskie (Warsaw, Poland : 1960), 1984
W, Kostowski, A, Płaznik
openaire   +1 more source

Antidepressant medications have differential effects on REM sleep without atonia quantified by chin and upper extremity EMG. [PDF]

J Clin Sleep Med
Ahdab JE, Rodriguez CL, Grigg-Damberger M, Araujo MLD, Andrews ND, Thanaviratananich S, Foldvary-Schaefer N.   +6 more
europepmc   +1 more source

Prediction model for medication adherence using a medication event monitoring system in recurrent major depressive disorder. [PDF]

Behav Pharmacol
Lin P, Hou C, Ji J, Chen Z.
europepmc   +1 more source

Recurrent serotonin syndrome during low-dose venlafaxine treatment in a patient with reduced CYP2D6 activity. [PDF]

BMJ Case Rep
Bouti LNA, Graenicher A, Simona A, El Rida El Masri A, Samer CF.   +4 more
europepmc   +1 more source

Response to Durability of zuranolone in postpartum depression versus major depressive disorder. [PDF]

Psychiatry Clin Neurosci
Kato M, Nakagome K, Baba T, Sonoyama T, Fukuju H, Shimizu R, Gomez JC, Motomiya T, Inoue T.   +8 more
europepmc   +1 more source

Ketamine for comorbid treatment-resistant depression and substance use disorders: balancing risks and opportunities. [PDF]

Pharmacol Rep
Brody BD, Kanellopoulos D.
europepmc   +1 more source